Orthofix Medical Inc. Compliance and Ethics Committee Charter

This charter governs the operations of the Compliance and Ethics Committee (the "Committee") of the Board of Directors (the "Board") of Orthofix Medical Inc. (the "Company"). The Committee shall review and assess the adequacy of this charter at least annually and recommend any proposed changes to the full Board.

1. Purpose

The Committee shall act on behalf of, and provide assistance to, the Board in overseeing, monitoring, and evaluating:

(a) the activities and the effectiveness of the Company's Global Compliance and Ethics Program;

(b) the activities and the effectiveness of the Company's Global Quality and Regulatory Program;

(c) the Company's compliance with applicable laws, rules, and regulations (collectively, "Applicable Law"), including those related to compliance with requirements of United States federal healthcare programs, requirements of the U.S. Food and Drug Administration, requirements of the European Commission of EU, and requirements of the U.S. Foreign Corrupt Practices Act and other applicable anti-corruption laws, and requirements of similar laws of other jurisdictions in which the Company does business, but excluding those related to financial reporting and disclosure matters and similar requirements under U.S. federal securities laws (which are overseen, monitored and evaluated by the Audit and Finance Committee of the Board);

(d) the Company's compliance with the terms of settlement agreements that the Company or a subsidiary enters into with governmental authorities, as applicable;

(e) the Company's compliance with the Company's own Code of Conduct, policies, and procedures; and

(f) trends and best practices that could affect the Company's business, Global Compliance and Ethics Program, and Global Quality and Regulatory Program

In so doing, the Committee shall seek to maintain unrestricted and open communication between the members of the Committee and the Quality, regulatory and compliance-related personnel of the Company (including the Company's Chief Ethics and Compliance Officer ("CECO"), the Senior Vice President of Global Regulatory, Quality and Clinical Affairs, and the Chief Legal and Development Officer), and to endeavor to foster a culture of compliance and ethical behavior throughout the Company. The Committee shall have full power and authority to discharge all of its duties and responsibilities.

2. Membership

The Committee shall be comprised of at least three directors of the Company who are appointed to the Committee by the Board. Members of the Committee shall serve until a successor is duly appointed by the Board or until the member resigns or is removed. The Board may remove any member from the Committee at any time, with or without cause. Each member of the Committee shall have been determined by the Board to be an "independent director" as defined in Nasdaq Marketplace Rule 5605(a)(2). To the fullest extent permitted by applicable law, any actions taken by the Committee during any period in which any member (or members) fails for any reason to meet the membership requirements set forth above shall nevertheless be duly authorized actions of the Committee for all corporate purposes.

3. Committee Structure and Operations

The Board shall designate one member of the Committee as its chairperson. The Committee shall meet in person or virtually at least four times a year and at other times as deemed necessary or desirable by the Committee or its chairperson. The Committee may also take action by unanimous written consent. The Committee may establish its own procedures in a manner not inconsistent with this charter, the Company's certificate of incorporation, bylaws and other corporate governance documents, applicable laws, regulations or listing standards (collectively, "Governance Requirements").

In discharging its role, the Committee is empowered to investigate any matter brought to its attention with full access to all books, records, facilities, and personnel of the Company. The Committee has the authority to engage independent counsel and other advisers, at the Company's expense, as the Committee may determine necessary to carry out its duties. The Committee may request that any directors, officers or employees of the Company, or other persons whose advice and counsel are sought by the Committee, attend any meeting of the Committee to provide such information as the Committee requests.

4. Duties and Responsibilities

(a) In general, the Committee shall endeavor to promote the Company operating in accordance with Applicable Law on an ongoing basis, with an appropriate overall corporate "tone" for compliance and ethical business practices.

(b) In particular, the Committee shall—

1. Oversee, monitor, and evaluate continuing development and implementation of a Global Compliance and Ethics Program, including the Company's Code of Conduct and compliance policies and procedures designed to prevent and detect violations of law.

2. Oversee, monitor, and evaluate continuing development and implementation of a Global Quality and Regulatory Program, including compliance with US FDA Quality Guidelines, European Medical Device Regulations, and quality and regulatory policies and procedures designed to ensure compliance with laws and regulations applicable to the Company products globally.

3. Appoint and oversee the activities of the Company's CECO, who has responsibility for continually developing and implementing the Company's Global Compliance and Ethics Program.

4. Review the activities of the Company's Senior Vice President of Global Quality and Clinical Affairs, who, among other things, has responsibility for continually

developing and implementing the Company's Global Quality and Regulatory Program

5. Oversee, monitor, and evaluate the Company's implementation as part of its Global Compliance and Ethics Program of:

   i. effective training and education in compliance;

   ii. effective lines of communication regarding compliance matters;

   iii. appropriately designed internal monitoring and auditing;

   iv. regular enforcement of compliance standards; and

   v. prompt responses to detected noncompliance, and undertaking of appropriate corrective action.

6. Oversee, monitor, and evaluate the Company's compliance with and implementation of the terms of any settlement agreements entered into with governmental authorities or warning letters and other directives issued by government agencies to correct or prevent regulatory violations.

7. Recommend such actions or measures to be adopted by the Board that the Committee deems appropriate to improve the effectiveness of the Company's Global Compliance and Ethics Program and the Company's Global Quality and Regulatory Program.

(c) In the performance of its duties, the Committee shall perform the following specific activities:

1. Annually, the Committee shall perform, or have performed, an evaluation of the performance of the CECO and the Company's compliance function and personnel.

2. Annually, the Committee shall review and approve an annual Global Compliance and Ethics Program plan developed by the CECO.

3. Annually, the CECO shall provide, and the Committee shall review, an annual Compliance and Ethics Program report, summarizing compliance-related activities undertaken by the Company during the year and the results of all compliance audits conducted during the year.

4. At least quarterly, the Committee shall meet with, and receive reports from, the CECO regarding the CECO's performance and activities, the performance and activities of the Company's compliance function and personnel, and the operations of the Company's Global Compliance and Ethics Program generally.

5. At least quarterly, the Committee shall report to the members of the Board (including at any meeting of the Committee at which all members of the Board are present) regarding activities of the Committee and the effectiveness of the Company's Global Compliance and Ethics Program and Global Quality and Regulatory Program.

6. Review, as generated, new and ongoing compliance hotline reports and compliance investigations maintained in the Company's third-party case management system.

7. Review and consider, as relevant, legal, compliance, and/or industry changes that may affect Orthofix's global operations,Global Compliance and Ethics Program and Global Quality and Regulatory Program.

(d) The Committee shall perform such other duties and responsibilities as may be assigned to the Committee by the Board.

(e) It is the intention of the Board and the Committee that all communications with the Company's CECO and Chief Legal and Development Officer, and any inside or outside legal counsel (including without limitation those described above) shall be deemed to constitute communications for the purpose of obtaining legal advice and are therefore privileged attorney-client communications.

5. Governance Requirements

The chairperson of the Committee or a majority of the Committee members may call meetings of the Committee at any time and for any reason. The notice of meeting need not include specified agenda items and must be provided to the Committee members no less than 24 hours prior to any meeting using any method available under the Governance Requirements. Attendance at any meeting of the Committee shall constitute a waiver of the notice requirement by such member. Meetings may be held using any form of communications equipment, so long as all directors can communicate with each other in real-time, including, but not limited to, via conference call, e-mail, instant messaging or otherwise using a virtual platform. A majority of the Committee members will constitute a quorum for the transaction of Committee business, and the vote of a majority of the Committee members present at a meeting at which a quorum is present will be the act of the Committee, unless in either case a greater number is required by the Governance Requirements. Additionally, the Committee may act by unanimous written consent of all Committee members, or by unanimous consent evidenced by any other form of communication, whether or not directly involving the physical transmission of paper, that creates a record that may be retained, retrieved, and reviewed by a recipient thereof, and that may be directly reproduced in paper form by such a recipient through an automated process, unless such action in such matter is expressly prohibited by the Governance Requirements.

Last revised on September 22, 2021